Medical Technical Directory:
Comparative Effectiveness Review of Antimicrobial Central Venous Catheters



Focus of Report: Antimicrobial central venous catheters (AMCVCs) are intended to prevent central line-associated bloodstream infections (CLABSIs) by coating or otherwise incorporating external and/or internal surfaces of the catheter with an antimicrobial agent. Some of the compounds used on currently marketed catheters include the antiseptic combination of chlorhexidine and silver sulfadiazine (C-SS); the antibiotic combination of minocycline and rifampicin (M-R); and a compound of silver, platinum, and carbon black (SPC).

Technology Description: AMCVCs are a type of central venous catheter (CVC) coated with antimicrobial agents, such as M-R, C-SS, or SPC.

Health Problem: CLABSIs have a high rate of mortality among hospital-acquired infections. These infections pose such a high risk because patients who require CVCs are usually acutely ill or highly immunosuppressed.

Patient Population: AMCVCs are indicated for short- or long-term use for venous pressure monitoring, blood sampling, administration of drugs and fluids, acute hyperalimentation, and power injection of contrast media.

Evidence Base: A total of 19 studies, including 18 prospective randomized controlled trials (RCTs) and 1 prospective randomized comparative trial evaluating AMCVCs for the prevention of CLABSIs, published from 1997 through January 15, 2018.

Download the report to continue reading…

  • *denotes required field
Privacy Policy
We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand where our visitors are coming from. By browsing our website, you consent to our use of cookies and other tracking technologies.
Thanks for signing up. You must confirm your email address before we can send you. Please check your email and follow the instructions.